133 related articles for article (PubMed ID: 36731587)
1. The Socioeconomic Impact of Irritable Bowel Syndrome: An Analysis of Direct and Indirect Health Care Costs.
Bosman MHMA; Weerts ZZRM; Snijkers JTW; Vork L; Mujagic Z; Masclee AAM; Jonkers DMAE; Keszthelyi D
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2660-2669. PubMed ID: 36731587
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
Buono JL; Carson RT; Flores NM
Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
4. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome.
DiBonaventura M; Sun SX; Bolge SC; Wagner JS; Mody R
Curr Med Res Opin; 2011 Nov; 27(11):2213-22. PubMed ID: 21951105
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
9. Review article: the economic impact of the irritable bowel syndrome.
Canavan C; West J; Card T
Aliment Pharmacol Ther; 2014 Nov; 40(9):1023-34. PubMed ID: 25199904
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
[TBL] [Abstract][Full Text] [Related]
12. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
[TBL] [Abstract][Full Text] [Related]
13. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
Goodoory VC; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2022 Jul; 56(1):110-120. PubMed ID: 35491477
[TBL] [Abstract][Full Text] [Related]
14. The burden of illness of irritable bowel syndrome: current challenges and hope for the future.
Hulisz D
J Manag Care Pharm; 2004; 10(4):299-309. PubMed ID: 15298528
[TBL] [Abstract][Full Text] [Related]
15. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
Brenner DM; Sayuk GS; Abel JL; Burslem K
J Manag Care Spec Pharm; 2021 Apr; 27(4):469-477. PubMed ID: 33769858
[No Abstract] [Full Text] [Related]
16. Evidence-based management of irritable bowel syndrome with diarrhea.
Pimentel M
Am J Manag Care; 2018 Jan; 24(3 Suppl):S35-S46. PubMed ID: 29372991
[TBL] [Abstract][Full Text] [Related]
17. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem.
Frändemark Å; Törnblom H; Jakobsson S; Simrén M
Am J Gastroenterol; 2018 Oct; 113(10):1540-1549. PubMed ID: 30254230
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
Goodoory VC; Guthrie EA; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2023 Feb; 57(3):323-334. PubMed ID: 36544055
[TBL] [Abstract][Full Text] [Related]
19. Annual Costs of Care for Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome.
Hoekman DR; Rutten JM; Vlieger AM; Benninga MA; Dijkgraaf MG
J Pediatr; 2015 Nov; 167(5):1103-8.e2. PubMed ID: 26329806
[TBL] [Abstract][Full Text] [Related]
20. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]